Search

A list of clinical trials in oncology, and surgical infection or sepsis is presented. The list includes "A randomized clinical trial comparing laparoscopic and open surgery for rectal cancer," by professors H. J. Bonjer and A. M. Lacy, "ROMIC: Role of ovarian metastasis in colorectal cancer," by R. M. H. Roumen, "CLIVIT: Clips vs. Ligatures. A multicenter randomized controlled trial," by professor M. W. Büchler, and others.

The article provides a list of clinical trials useful for researchers that are in progress throughout the world including, the Cancer Research UK, Bayer AG, cancer prevention project by Prof. John Burn, University of Newcastle, UK; Ethicon Endosurg funded trials on rectal cancer by Prof. H.J. Bonjer and Prof. A.M. Lacy; necrotizing pancreatitis by Prof. H.G. Gooszen funded by The Netherlands Organization for Health Research.

Presents a chart that lists ongoing clinical trials related to gastroenterology as of September 2005.

The section presents information on ongoing clinical trials related to oncology and inflammatory bowel disease, as of July 2004. A randomized controlled trial of colorectral polyp and cancer prevention is being conducted by John Burns. A trial comparing laparoscopic and open surgery for rectal cancer is being conducted by H. J. Bonner and A. M. Lacy. The safety and efficacy of two dose regimens of CPB-1011 in patients with Crohn's disease is being investigated.

Aim: To investigate genotype-phenotype correlations in patients with perianal Crohn's disease (PCD) in order to determine which factors predispose to development of perianal disease in Crohn's patients., Methods: Seven-hundred and ninety-five Caucasian individuals (317 CD patients and 478 controls without inflammatory bowel disease, IBD) were prospectively enrolled into a clinical/genetic database. Demographic and clinical data, as well as peripheral blood leukocyte DNA were obtained from all patients. The following were evaluated: three NOD2/CARD15 polymorphisms: R702W, G908R, and 1007insC; five IL-23r risk alleles: rs1004819, rs10489629, rs2201841, rs11465804, and rs11209026; a well-characterized single-nucleotide polymorphism (SNP) on the IBD5 risk haplotype (OCTN1) and two peripheral tag SNPs (IGR2060 and IGR3096)., Results: PCD occurred in 147 (46%) of CD patients. There was no significant difference in the age at disease diagnosis between non-PCD and PCD patients (33 vs. 29 years, respectively). PCD patients were more likely to have disease located in the colon and ileocolic regions (79 PCD vs. 57% non-PCD; n = 116 vs. n = 96; p < 0.001), whereas patients with non-PCD were more likely to have Crohn's within the terminal ileum and upper gastrointestinal tract (43% non-PCD vs. 21% PCD; n = 73 vs. n = 31; p < 0.05). Thirty-four percent of patients with PCD required a permanent ileostomy (n = 50) compared to only 4% of non-PCD patients (n = 6; p < 0.05). Mutations in CARD15/NOD2 and IL-23r were risk factors for CD overall; however, in contrast to prior reports, in this patient population, OCTN1 and IGR variations within the IBD5 haplotype were not significant predictors of PCD., Conclusion: Colon/ileocolic CD location appears to be a significant predictor of perianal manifestations of CD. Patients with PCD are more likely to require permanent fecal diversion. We did not identify any genetic variations or combination of clinical findings and genetic variations within the CARD15/NOD2, IL-23r, and OCTN1 genes or IGR that were predictive of PCD., (Copyright © 2012 S. Karger AG, Basel.)

Background/aims: Many tumor markers have been utilized in the follow-up care of colorectal cancer patients. No marker, however, has proven reliably accurate in detecting recurrent disease., Methods: The strengths and weaknesses of currently available tumor markers are reviewed, with attention to related cost and efficacy., Results: Tumor antigens, enzymes, and genetic markers have been used as tumor markers. CEA and CA 19.9 are the most widely utilized; however, genetic markers are the most promising for the future., Conclusions: Currently available markers have significant limitations. Development of genetic markers may greatly enhance our ability to predict prognosis and the need for adjuvant therapy. Marker-guided therapy may play an increasing role in this disease., (Copyright 2000 S. Karger AG, Basel)

There is controversy regarding the frequency of sedation-related complications of colonoscopies and whether these procedures are safely performed by physicians-in-training. We retrospectively reviewed the safety of 1,004 consecutive outpatient colonoscopies. No perforations occurred. No patients were hospitalized for sedation-related complications. Seventeen percent of patients had significant changes in vital signs that lasted less than 5 min. These changes were less common in patients receiving